Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in chronic heart failure with preserved ejection fraction
NL-OMON49597Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Composite of cardiovascular death or hospitalization for heart failure. Started Apr 2017; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON49597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49597.